Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests ...

A Durham company is pushing back on media reports questioning the safety of its lead product as the firm begins its commercial launch.

Arcutis Biotherapeutics wants to eliminate a terrible trade-off for patients with skin conditions. Arcutis stock investors are taking notice.

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

The Global Single-cell Analysis Market is projected to grow at a CAGR of 9.5% from 2026 to 2033, according to a new report published by Verified Market Reports ®. The report reveals that the market ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Received Clearance from the U.S. Food and Drug Administration (FDA) for Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), ...

Millions of people will find that their DNA data has been put up for sale as the human genetics company enters Chapter 11 administration.

This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...